|
at 01:05 |
|
|
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced today that four abstracts with Innate's drug candidates have been accepted for the European Association of Hematology (EHA) 2024 Congress,...
|
|
at 01:05 |
|
|
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target for Heart Failure to its discovery portfolio...
|
|
at 00:01 |
|
|
America's child care supply remains flat, while child care prices continue to increase, according to a new report released today by Child Care Aware® of America (CCAoA) that highlights the burden families face accessing quality and affordable child...
|
|
at 00:01 |
|
|
The cost of living is Gen Zs' and millennials' top societal concern, but green shoots of optimism for the economy and their personal finances are emergingNearly nine in 10 Gen Zs and millennials say purpose is important to their job satisfaction and...
|
|
at 00:00 |
|
|
AmacaThera Inc, a clinical stage biotechnology company specializing in the development of advanced sustained release hydrogel formulations, has dosed its first human subject with AMT-143, the company's lead asset in non-opioid acute pain management. ...
|
|
14 mai 2024 |
|
|
BioArctic AB's (publ) partner Eisai today said that they expect Leqembi sales to total JPY 56.5 billion (approximately SEK 4 billion) for their fiscal year (FY) 2024 (April 2024 through March 2025). This would generate approximately SEK 360 M in net...
|
|
|
